CJC-1295 isn't found on pharmacy shelves in Datia or most other cities — this is a specialist compound distributed through a dedicated online market. What this means for Datia researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those verification methods are accessible to anyone. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis documenting HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. The sections below cover what Datia researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Datia comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
Before assessing any particular supplier, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be 98% or higher. For Datia researchers evaluating vendors with limited track records: a small initial order to verify quality before placing larger orders is standard practice in the community. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order CJC-1295 — ships to Datia
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that proper COA verification addresses. Protocol documentation — keeping clear records of compound, timing, and method — is a research best practice for CJC-1295 that ensures unusual findings can be explained.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
